Shareholder Protection: Sign It Before It Is Too Late

Most shareholders in small and medium UK companies discover the true state of their share protection arrangements only when a fellow director becomes seriously ill, which is precisely the wrong time to find gaps. Without a properly executed shareholder protection agreement covering the death of a shareholder, the shares of a director who dies simply pass under their will, or under the intestacy rules if there is none, to whoever inherits them: a spouse, a child, or anyone else named. The other directors have no automatic right to buy those shares back, and the family has no automatic right to insist the company or its directors buy them either.

A terminal diagnosis, difficult as it is, is often the last realistic opportunity to put this right, because the cross-option agreement and any trust over the supporting insurance policy must be signed by the shareholder personally, while they still have capacity to do so. Once that capacity is gone, an attorney cannot execute either document on their behalf, and the company is left relying on whatever the existing articles of association happen to say, which in many smaller companies is very little.

What happens to shares when a shareholder dies, with no agreement in place

Company shares are simply an asset like any other for succession purposes, unless the articles of association or a separate shareholders' agreement say otherwise. On death, they pass under the deceased's will to whoever is named as a beneficiary, or under the intestacy rules to the closest qualifying relatives if there is no will. There is nothing in ordinary company law that automatically hands them back to the surviving directors, and nothing that automatically obliges the family to sell.

The consequences of this are often more disruptive than either side expects. A spouse or adult child with no experience of the business, and often no wish to be involved in it, can become a shareholder overnight, potentially entitled to see company accounts, attend general meetings and vote on resolutions. The surviving directors, meanwhile, may find themselves running a company with a new owner they did not choose and cannot simply remove, since minority shareholder protections in the Companies Act and the company's own articles generally prevent the majority from forcing out an unwilling shareholder without proper process. What happens to a director's shares if there is no will at all sets out the intestacy version of this problem in more detail.

Equally, the family may find they have inherited shares in a private company that has no ready market, no obligation on anyone to buy them, and no dividend income if the surviving directors choose not to declare one. An asset that looks valuable on paper can be genuinely difficult to turn into cash, which is often not what a grieving family expected or needed.

What a cross-option agreement actually does

A cross-option agreement, sometimes called a double option agreement, is the standard solution to this problem in UK company law. It gives the surviving shareholders an option to buy the deceased's shares, and gives the deceased's personal representatives an option to sell them, at a price usually set by a pre-agreed formula or a valuation mechanism written into the agreement itself. Each side must complete the sale if the other side chooses to exercise its option, but crucially, neither side is obliged to exercise it in the first place.

That last point, that the arrangement is a pair of options rather than a binding obligation to buy and sell, is deliberate and matters for tax reasons. A binding contract for sale made in advance, sometimes called a buy-and-sell agreement, can be treated by HM Revenue and Customs as removing the shares from the scope of business property relief, because the deceased is treated as having already agreed to sell them for cash rather than continuing to hold genuine business property up to the point of death. A cross-option structure, where nothing is compelled unless and until an option is actually exercised after death, is generally considered more likely to preserve that relief, though the position depends on the detail of the drafting and professional advice should confirm it for any specific company. Business property relief and shares left to someone unable or unwilling to be a director explores a related situation where the same relief is at stake.

Source: HM Revenue and Customs, Inheritance Tax Manual on business property relief, gov.uk.

The insurance that funds a cross-option agreement is normally a life policy on each shareholder, arranged so that the proceeds provide the surviving shareholders with the cash to exercise their option to buy, without having to find the money from company funds or personal savings at short notice. Getting the amount of cover right, and keeping it aligned to a business's changing value, is its own ongoing task; working out how much cover a small company actually needs covers the equivalent calculation for key person cover, and the same principles of regularly reviewing sums assured apply here.

Why capacity, not just paperwork, is the real deadline

Both the cross-option agreement and any trust arrangement over the supporting life policy are legal documents that must be executed personally by the shareholder they concern. This is not a formality that can be delegated. A lasting power of attorney, however comprehensive, generally does not extend to an attorney signing this kind of agreement on the donor's behalf, because it involves giving up or restructuring the donor's own property rights in a way that goes well beyond routine financial management.

This is why a terminal diagnosis changes the calendar so sharply. While a shareholder retains mental capacity, however unwell they are physically, the agreement can still be drafted, explained, and signed in the ordinary way, sometimes within days if a solicitor is engaged promptly. Once capacity is lost, whether through the progression of the underlying illness, medication, or a related event such as a stroke, the option of putting a fresh agreement in place closes, and the company is left with whatever protection, if any, was arranged years before. Directors who have been meaning to "get round to" shareholder protection often discover, at exactly the wrong moment, that meaning to is not the same as having done it.

If the diagnosis has followed a period without any director death-in-service or business protection cover at all, this is also the moment to check what else may be missing; what happens if a sole director had no death-in-service benefit covers a closely related gap that often exists alongside a missing cross-option agreement, and both are worth reviewing together rather than in isolation.

What to do this week if a diagnosis has just been given

If a shareholder in your company has recently received a serious diagnosis and no cross-option agreement exists, treat this as urgent rather than something to schedule for next quarter. Speak to a solicitor experienced in shareholder agreements as soon as possible, ideally the same week, and be candid about the timescale, since a solicitor familiar with the situation can prioritise drafting and execution accordingly. If existing life policies on the shareholders are not already written into an appropriate trust to support the arrangement, that too needs arranging while capacity remains, and a broker or adviser experienced in business protection can usually move quickly once instructed. Companies without any existing cover in place can get life insurance quotes as a starting point, though a cross-option structure specifically needs advice tailored to company and shareholder circumstances rather than a general policy alone.

It is also worth checking the company's existing articles of association at the same time, since some articles already contain pre-emption rights or transfer restrictions that partially address this problem, and understanding what is already there avoids duplicating or contradicting it in a new agreement.

Getting the valuation mechanism right

A cross-option agreement is only as useful as the price it produces when an option is exercised, and this is a detail worth getting right rather than leaving to a vague formula. Some agreements fix a price in advance and update it periodically, which is simple but can become badly out of date if the business grows quickly or its fortunes change between reviews. Others specify an independent valuation at the time an option is exercised, usually by the company's accountants or an agreed independent valuer, which better reflects the business as it actually is on the day but takes longer to produce and can itself become a point of disagreement between the surviving directors and a grieving family if the numbers are contested.

Whichever mechanism is chosen, it should be reviewed periodically alongside the level of insurance cover in place, since a valuation formula and a sum assured that were sensible five years ago can drift apart just as easily as a mortgage and a decreasing insurance policy can. A company that has grown substantially since the agreement was first signed may find the insurance proceeds no longer stretch to buying out the shares at the price the formula now produces, which defeats much of the purpose of having arranged the cover in the first place.

Telling the family what to expect

One part of this process that is easy to overlook is communication with the shareholder's own family, ideally well before any diagnosis is on the horizon, but certainly once one has been given. A spouse or adult child who understands, in advance, that the shares will be bought out under an existing agreement, roughly what that is likely to be worth, and roughly how quickly the money should arrive, is in a far better position than one discovering all of this for the first time in the days after a death. It also reduces the chance of the family feeling, understandably, that they are being asked to give something up rather than receiving what was always intended for them.

Where the family will also be dealing with a mortgage, other debts, or day-to-day household costs while the company side of things is being resolved, it is worth pointing them towards the wider practical steps involved in making a terminal illness claim on personal life cover held separately from the business, since the two processes, personal and business protection, usually run in parallel rather than one waiting for the other.

Scotland and Northern Ireland

Company law, including the rules on shares, articles of association and business property relief, is largely reserved and applies uniformly across the whole of the UK, so the mechanics of a cross-option agreement described here work the same way in a company registered in Scotland or Northern Ireland as in England and Wales. Where local rules can still bite is in how a deceased shareholder's estate is administered more generally: Scotland uses confirmation rather than probate, and its legal rights regime can give a spouse or children an automatic claim against moveable estate, including shares, that does not exist in the same form south of the border. How Scottish legal rights can affect children's claims against an estate explains this in more detail for anyone structuring share succession alongside a Scottish estate.

Frequently asked questions

What happens to my shares if I die?

They pass under your will, or under the intestacy rules, unless the articles or a shareholders' agreement say otherwise. Your family may end up owning part of a business they cannot run or sell, while the surviving directors have no automatic right to buy them.

What does a cross-option agreement do?

It gives the surviving shareholders an option to buy and the deceased's estate an option to sell, and each side must complete if the other exercises. Because neither party is bound to act until an option is exercised, it is normally drafted to preserve business property relief.

Why does capacity matter?

The agreement, and any trust over the policy, must be signed by the shareholder personally. An attorney cannot execute them, so delay until capacity is lost leaves the company relying on whatever the articles happen to say. After a diagnosis, this is a matter of days rather than months.